A Series of Enzyme-Controlled-release Polymer-Platinum-based Drug Conjugates for the Treatment of Gastric Cancer

Tianyi Shi,Lianshuai Gu,Yu Sun,Senlin Wang,Xiangyang Zhang,Jin Zhu,Baiwang Sun
DOI: https://doi.org/10.1016/j.eurpolymj.2017.03.039
IF: 6
2017-01-01
European Polymer Journal
Abstract:Platinum-based drugs are widely used as a master key in the multiple cancer therapies, while limited by the adverse side effects during the in vivo circulation. To settle the aforementioned problems, we prepare a series of polymer-platinum conjugates by utilizing the "stealth" polyethylene glycol and legumain-cleavable oligopeptide.We select MGC803 cells overexpressing the legumain and MKN28 cells negatively expressing the legumain as well as the normal stomach cells to compose the test groups.In vitro cytotoxicity studies indicate the polymer-platinum conjugates with the assistance of Ala-Ala-Asn tripeptide can effectively inhibit the growth of MGC-803 cells than control groups. Meanwhile, the MPEG polymer show better anticancer ability than 4-arm-PEG polymer. However, in the group of MKN28 cells, both polymer-platinum conjugates express weak cytotoxicity due to lacking of the mediation of legumain.Hence, the synthesized polymer-platinum conjugates exhibiting great potential in avoiding the side effects and enhancing the therapy ability will be valuable for the platinum-cancer therapy.
What problem does this paper attempt to address?